Formulation Optimization of Chitosan Stabilised Silver Nanoparticles using In-vitro Antimicrobial Assay.

Related Articles

Formulation Optimization of Chitosan Stabilised Silver Nanoparticles using In-vitro Antimicrobial Assay.

J Pharm Sci. 2018 Sep 19;:

Authors: Pansara C, Chan WY, Parikh A, Trott DJ, Mehta T, Mishra R, Garg S

Abstract
Antimicrobial resistance at the infected site is a serious medical issue that increases patient morbidity and mortality. Silver has antibacterial activity associated with some dose dependent toxicity. Silver nanoparticles, due to larger surface area, have antibacterial properties which make them useful in the treatment of infections. Chitosan stabilised silver nanoparticles (CH-AgNP) were formulated and evaluated for minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) testing against Staphylococcus aureus ATCC 29213, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922 and 20 methicillin-resistant S. aureus (MRSA) isolates. Minimum biofilm eradication concentration (MBEC) study was used to evaluate the biofilm reduction andin-vitro antimicrobial checkerboard assays were performed. The effective optimum ratio of AgNP: chitosan solution was 1:4. MIC and MBC ranges of CH-AgNP were 4 to 14 times lower compared to AgNP alone against MRSA isolates. MBEC values of CH-AgNP for ATCC PA-01, P. aeruginosa isolate 1 and P. aeruginosa isolate 2 were found to be > 84.59 μg/mL, 42.29 μg/mL, and 21.15 μg/mL, respectively. Thus, CH-AgNP is a potential formulation for wound treatment and management of infected sites associated with antimicrobial resistance.

PMID: 30244012 [PubMed - as supplied by publisher]